790 related articles for article (PubMed ID: 28833562)
1. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
2. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
[TBL] [Abstract][Full Text] [Related]
3. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
4. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
[TBL] [Abstract][Full Text] [Related]
5. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ
J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Pajo AT; Espiritu AI; Jamora RDG
Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922
[No Abstract] [Full Text] [Related]
7. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
9. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D;
Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940
[TBL] [Abstract][Full Text] [Related]
10. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Elkurd MT; Bahroo LB; Pahwa R
Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954
[TBL] [Abstract][Full Text] [Related]
11. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
[TBL] [Abstract][Full Text] [Related]
12. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
[TBL] [Abstract][Full Text] [Related]
13. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Hauser RA; Kremens DE; Elmer LW; Kreitzman DL; Walsh RR; Johnson R; Howard R; Nguyen JT; Patni R
J Parkinsons Dis; 2019; 9(3):591-600. PubMed ID: 31081793
[TBL] [Abstract][Full Text] [Related]
15. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
[TBL] [Abstract][Full Text] [Related]
16. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
[TBL] [Abstract][Full Text] [Related]
17. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
18. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
19. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
[TBL] [Abstract][Full Text] [Related]
20. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
